Product Launch
April 16 2009 - 1:00AM
RNS Non-Regulatory
TIDMUTK
UTEK Corporation
16 April 2009
?
16 April 2009
UTEK Corporation
Pharmalicensing and ICE Pharma Group Announce the Launch of Genericlicensing.com
Tampa, FL, Berks & York, England -- (Business Wire) - April 16, 2009 -- UTEK
Corporation (NYSE Alternext US & LSE-AIM: UTK), a leading innovation services
company is pleased to announce the launch of a new website,
www.genericlicensing.com. The site represents a joint venture between UTEK's
Pharmalicensing division and ICE Pharma Group.
Genericlicensing.com has been developed to become an essential business tool for
licensing and contract developments for the generic pharmaceutical sector. The
site provides a comprehensive database of approved, available and in-development
generic products.
There are a number of key features and tool-sets that will now make the task of
obtaining new generic products easier for paid subscribers:
* Product detail - all the required data and information for quick decision making
* Product updates - reduce frequent email exchanges with developers
* Offer and counter-offer tools - compile all information in a web based interface
for simple evaluation
* Product requests - ask developers if they would consider a new product
development
The site also offers hands-on business development services to complement the
online activities:
* Partner surveys - search through the vast network of contacts to find suitable
products/partners
* Project planning, initiation and closure - part or all of the licensing process
can be outsourced
* Market assessments - a comprehensive country report is essential before entering
a market
Mark McBride, Director of Pharmalicensing, commented, "We are all delighted to
have entered into this joint venture for the creation of Genericlicensing.com.
We feel that it will offer a valuable tool for generic companies of all sizes to
rapidly identify products for licensing from reliable and pre-screened sources
from around the world. We look forward to working closely with ICE Pharma Group
to provide these services through Genericlicensing.com for the benefit of all
companies working in the sector."
Asa Cox, Strategic Business Development Director at ICE stated, "Using the power
of Pharmalicensing's existing platform, tailored to the generics industry, and
leveraging ICE's expertise, we feel the partnership has created an extremely
useful business tool. Already we have over 150 subscribers looking for products;
from both large generic companies and local firms from around the world. We
believe Genericlicensing.com will become an essential part of the way the
generics industry does business."
For more information see www.genericlicensing.com.
About UTEK Corporation
UTEKis a leading innovation services company. UTEK's services enable clients to
become stronger innovators, rapidly source externally developed technologies,
create value from their intellectual property and gain foresight into
marketplace and technology developments that affect their business. UTEK is a
business development company. For more information about UTEK, please visit its
website at www.utekcorp.com.
About Pharmalicensing
Pharmalicensing is the premier biopharmaceutical open innovation resource
designed for life science professionals involved with partnering, licensing and
business development worldwide. Actively supporting in- and out-licensing
activities, Pharmalicensing currently provides partnering services to over 200
client companies around the world. Pharmalicensing is a division of UTEK
Corporation. For more information, please visit its website at
www.pharmalicensing.com.
About ICE Pharma Group
ICE, established in 1998, is a pharmaceutical company which specializes in
sourcing, manufacturing services and business development in the generics and
OTC market sectors. ICE started life as a pharmaceutical active ingredients
(APIs) trading company with an emphasis on the Far East; supporting large
generic companies with difficult to source and hard to manage APIs.
Building on this partner portfolio and a growing client base in Europe and USA,
ICE vertically integrated into finished formulations, offering both contract
manufacturing services and registration dossiers. In 2004 ICE made the strategic
move to transform its manufacturing relationships in to strategic partnerships
and carefully matched joint ventures; compounding the benefits of its history
and enabling it to launch its own generic products into select markets.
Today the ICE Pharma Group of companies offers a range of services and
manufacturing options across the generic pharmaceutical market sector utilizing
its skills, strategic partnerships and licensing network. For more information
about ICE Pharma Group, please visit its website at www.icepharmagroup.com.
Forward-Looking Statements
Certain matters discussed in this press release are "forward-looking
statements." These forward-looking statements can generally be identified as
such because the context of the statement will include words, such as UTEK or
ICE Pharma Group "expects," "should," "believes," "anticipates" or words of
similar import. Similarly, statements that describe UTEK's or ICE Pharma Group's
future plans, objectives or goals are also forward-looking statements. Such
forward-looking statements are subject to certain risks and uncertainties, which
could cause actual results to differ materially from those currently
anticipated. Although UTEK and ICE Pharma Group believe the expectations
reflected in any forward-looking statements are based on reasonable assumptions,
it cannot give any assurance that its expectations will be attained.
Shareholders, potential investors and other readers are urged to consider these
factors carefully in evaluating any forward-looking statements. Certain factors
could cause results and conditions to differ materially from those projected in
these forward-looking statements, and some of these factors are discussed below.
These factors are not exhaustive. New factors, risks and uncertainties may
emerge from time to time that may affect the forward-looking statements made
herein. These forward-looking statements are only made as of the date of this
press release and UTEK and ICE Pharma Group do not undertake any obligation to
publicly update such forward-looking statements to reflect subsequent events or
circumstances.
UTEK's operating results could fluctuate significantly due to a number of
factors. These factors include, levels of consulting activity, variability in
the growth rate of our business, consultant utilization rates, consultant and
project billing rates, and number of revenue-generating professionals; our
ability to expand our service offerings; that we successfully integrate the
businesses we acquire; challenging financial conditions, including those in the
credit markets, the number of transactions and engagements that are completed
each quarter, the value of individual contracts and transactions, the timing of
the recognition and the magnitude of unrealized and realized gains and losses of
companies in its portfolio, UTEK's dependence on the performance of its
operating divisions as well as the companies in its portfolio, the possibility
that advances in technology could render the technologies it has transferred
obsolete, the loss of technology licenses by companies in its portfolio, the
degree to which it encounters competition in its markets, the volatility of the
stock market and the volatility of the valuations of the companies it has
invested in as it relates to its realized and unrealized gains and losses, the
concentration of investments in a small number of companies, marketplace demand
for innovation consulting services as well as other general economic conditions.
For more information on UTEK and for a more complete discussion of the risks
pertaining to an investment in UTEK, please refer to UTEK's filings with the
Securities and Exchange Commission.
+---------------------------------------+
| Contacts: |
+---------------------------------------+
| UTEK Corporation & Pharmalicensing, |
| Ltd |
+---------------------------------------+
| USA: |
+---------------------------------------+
| Allen & Caron, Inc. |
+---------------------------------------+
| Brian Kennedy |
+---------------------------------------+
| brian@allencaron.com |
+---------------------------------------+
| 212-691-8087 |
+---------------------------------------+
+----------------------------------+
| ICE Pharma Group |
+----------------------------------+
| Asa Cox |
+----------------------------------+
| +44 (0) 870-752-4105 |
+----------------------------------+
| |
+----------------------------------+
| Genericlicensing.com |
+----------------------------------+
| Delia Freeman |
+----------------------------------+
| +44 (0) 870-752-4105 |
+----------------------------------+
| delia.freeman@icepharmagroup.com |
+----------------------------------+
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAIAMBTMMJBTIL
Utek Corp (LSE:UTK)
Historical Stock Chart
From Aug 2024 to Sep 2024
Utek Corp (LSE:UTK)
Historical Stock Chart
From Sep 2023 to Sep 2024